Radius Health, Inc. (RDUS) Rating Reiterated by Goldman Sachs Group, Inc. (The)

Goldman Sachs Group, Inc. (The) restated their neutral rating on shares of Radius Health, Inc. (NASDAQ:RDUS) in a research note issued to investors on Friday morning, MarketBeat.com reports. They currently have a $45.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on RDUS. ValuEngine raised Radius Health from a sell rating to a hold rating in a report on Thursday, June 22nd. BidaskClub raised Radius Health from a hold rating to a buy rating in a report on Tuesday, June 27th. Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Cantor Fitzgerald set a $58.00 price target on Radius Health and gave the company a buy rating in a report on Sunday, July 23rd. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Radius Health currently has a consensus rating of Hold and a consensus price target of $52.17.

Radius Health (NASDAQ:RDUS) opened at 37.74 on Friday. The firm’s 50-day moving average price is $36.65 and its 200 day moving average price is $38.74. The firm’s market cap is $1.64 billion. Radius Health has a 52 week low of $31.58 and a 52 week high of $55.97.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter in the prior year, the firm posted ($1.01) earnings per share. Equities analysts forecast that Radius Health will post ($5.55) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. (RDUS) Rating Reiterated by Goldman Sachs Group, Inc. (The)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/10/radius-health-inc-rdus-rating-reiterated-by-goldman-sachs-group-inc-the.html.

In other news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jose Carmona acquired 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the completion of the acquisition, the chief financial officer now owns 3,000 shares in the company, valued at approximately $98,490. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 469,100 shares of company stock worth $16,328,382. 15.00% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new position in shares of Radius Health during the 1st quarter valued at about $105,000. Sei Investments Co. raised its holdings in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Radius Health by 1.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the bioph

Several other research firms have also recently weighed in on RDUS. ValuEngine raised Radius Health from a sell rating to a hold rating in a report on Thursday, June 22nd. BidaskClub raised Radius Health from a hold rating to a buy rating in a report on Tuesday, June 27th. Zacks Investment Research raised Radius Health from a sell rating to a hold rating in a report on Tuesday, August 8th. Cantor Fitzgerald set a $58.00 price target on Radius Health and gave the company a buy rating in a report on Sunday, July 23rd. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Radius Health currently has a consensus rating of Hold and a consensus price target of $52.17.

Radius Health (NASDAQ:RDUS) opened at 37.74 on Friday. The firm’s 50-day moving average price is $36.65 and its 200 day moving average price is $38.74. The firm’s market cap is $1.64 billion. Radius Health has a 52 week low of $31.58 and a 52 week high of $55.97.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $1.96 million. During the same quarter in the prior year, the firm posted ($1.01) earnings per share. Equities analysts forecast that Radius Health will post ($5.55) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. (RDUS) Rating Reiterated by Goldman Sachs Group, Inc. (The)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/10/radius-health-inc-rdus-rating-reiterated-by-goldman-sachs-group-inc-the.html.

In other news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jose Carmona acquired 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average cost of $32.83 per share, for a total transaction of $98,490.00. Following the completion of the acquisition, the chief financial officer now owns 3,000 shares in the company, valued at approximately $98,490. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 469,100 shares of company stock worth $16,328,382. 15.00% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new position in shares of Radius Health during the 1st quarter valued at about $105,000. Sei Investments Co. raised its holdings in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Radius Health by 1.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,888 shares in the last quarter. Finally, Blair William & Co. IL purchased a new position in shares of Radius Health during the 2nd quarter valued at about $205,000.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply